Therapies

Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer

7 monthes ago   |   By Xconomy

Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases. It's an all-cash deal worth $3 billion, with the Astellas offer of $60 per share representing a 110 percent premium to Audentes' share price of $28.61 apiece at market close Monday. The agreement is the latest big bet by a major pharmaceutical company on gene therapy, which aims to provide long-lasting, if not permanent, disease treatments. San Francisco-based Audentes' lead drug candidate, AT132, is a clinical-stage...
Read more ...

 

Astellas inks $3B Audentes buyout to expand in gene therapy

Astellas inks $3B Audentes buyout to expand in gene therapy

7 monthes ago   |   By Fierce Biotech

Astellas Pharma is set to buy Audentes Therapeutics for $3 billion. The deal will enable Astellas to set up a new genetic regulation unit spearheaded by a neuromuscular disease gene therapy that is set to be submitted for approval next year.
Read more ...

 


Search by Tags

   Therapies      Pharmaceutical      Pharma      Therapeutics      Drugs      Drug      Pharmaceuticals      Clinical      Gene      Genes      Gene Therapy      National      National blog main      National top stories      San Francisco blog main      San Francisco top stories      Acquisition      Antitrust      Astellas Pharma      Audentes      Big Pharma      Biotech      Buyout      Clinical trials      Deals      Drug Pricing      FDA      Joseph Schwartz      Life Sciences      M&A      Mergers      Neuromuscular disease      Orbimed      Rare disease      Regulatory review      Roche      Spark      Spark Therapeutics      Startup      SVB Leerink      Genetics  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

Foghorn Therapeutics could receive up to $425 million in the development deal with Merck, its first partnership with a major biopharma. One way that a cell regulates which... Read more ...

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based... Read more ...

Data Migration: Being Prepared

Data Migration: Being Prepared

Our Professional Services Written by: Alan Pham, Business Development Associate In a world where our data is crucial to our everyday lives, implementing new platforms is... Read more ...

NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

The first drug for neurofibromatosis type 1 is available to patients following the FDA's approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection... Read more ...

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has... Read more ...

Biogen Alzheimer's Drug in FDA's Court Following Completion of Filing

Biogen Alzheimer's Drug in FDA's Court Following Completion of Filing

By early September Biogen-plus the many scientists, patients, and investors following the saga of its controversial Alzheimer's drug aducanamab-should know whether the FDA... Read more ...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period

The 2020 National Xconomy Awards - celebrating the best in biotech innovation and entrepreneurship - just got bigger! We're excited to announce the expansion of the 2020... Read more ...

Scientists Dive Deep Into Hidden World of Quantum States

Scientists Dive Deep Into Hidden World of Quantum States

Right: Animation of a Van Hove singularity shown approximately 1 nanometer below the surface of an oxide heterostructure made of atomically thin layers of strontium titanate... Read more ...

UFGI Publication round-up week 7/6/20

Manipulation of sensory characteristics and volatile compounds in strawberry fruit through the use of isolated wavelengths of light. Campbell SM, Sims CA, Bartoshuk LM... Read more ...

DNA Chisel, a versatile sequence optimizer

AbstractMotivationAccounting for biological and practical requirements in DNA sequence design often results in challenging optimization problems. Current software solutions are... Read more ...